UPDATE: Raymond James Downgrades Voyager Therapeutics (VYGR) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to UPDATE: Raymond James Downgrades Voyager Therapeutics (VYGR) to Outperform
November 9, 2020 4:00 PM EST
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its third quarter 2020 financial results, program progress and corporate updates.
During the third quarter, we took important steps to advance our lead programs for Parkinsons disease and Huntingtons disease with the presentation of positive long-term clinical results and the filing of an IND, respectively. Together with our partner, Neurocrine, we are currently focused on resuming enrollment in the RESTORE-1 clinical trial for Parkinsons disease pending the requested review and assessment of patient imaging data by the DSMB. For our... More
November 6, 2020 2:00 AM EST
CSE: VYGROTCQB: VYGVFBorse Frankfurt: UCD2
-- Voyager Management Scheduled to Participate at the 2020 Benzinga Global FinTech Awards event on November 10th -
NEW YORK, Nov. 6, 2020 /PRNewswire/ -Â Voyager Digital Ltd. ("Voyager" or the "Company") (CSE:... More
